INVO Fertility Announces Patent Issuance for Modified INVOcell® Device

Core Insights - INVO Fertility, Inc. has received a U.S. patent for a modified version of its INVOcell device, extending intellectual property protection until 2040 [1][4] - The INVOcell device is the first FDA-cleared intravaginal culture system, allowing fertilization and early embryo development within a woman's body, providing a more natural alternative to traditional IVF [2][5] Group 1: Patent and Intellectual Property - The newly issued patent (U.S. Patent No. 12,544,204 B2) became effective on February 10, 2026, marking a significant milestone for the company [1][4] - The patent covers a simplified design of the INVOcell device, which has been developed based on clinical feedback and real-world use [3] Group 2: Product and Market Position - INVOcell was initially granted FDA clearance in 2015 and received an update in 2023 to extend the recommended incubation period from three days to five days [3] - The INVOcell procedure is designed to provide a more connected and affordable experience for patients compared to traditional ART treatments, with the potential for comparable results at a lower cost [5]